Nymox Pharmaceutical Corp (NASDAQ:NYMX)

4.76
Data as of Sep 17
 +0.02 / +0.42%
Today’s Change
4.40
Today|||52-Week Range
7.90
-21.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$167.8M

Company Description

Nymox Pharmaceutical Corp. is a biopharmaceutical company, which specializes in the research and development of products for the aging population. Currently, it markets NicAlertTM and TobacAlertTM, tests that use urine or saliva to detect use of tobacco products. The company develops NX-1207, a novel treatment for benign prostatic hyperplasia, which is in Phase 3 clinical trials. It also has pipeline drug candidates aimed at the causes of Alzheimer's disease and new treatments of bacterial infections in humans. Nymox Pharmaceutical was founded by Paul Averback on May 30, 1995 and is headquartered in St.-Laurent, Canada.

Contact Information

Nymox Pharmaceutical Corp.
9900, boulevard Cavendish
Saint-Laurent Quebec H4M 2V2
P:(800) 936-9669
Investor Relations:

Employees

Shareholders

Other institutional3.44%
Mutual fund holders2.07%
Individual stakeholders--

Top Executives

Paul AverbackChairman, President & Chief Executive Officer
André MonetteChief Financial Officer
Jack GemmellDirector & Chief Information Officer
Brian DoyleDirector-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.